在智利患有多发性硬化症的患者中,Ocrelizumab的真实证据
Adolfo Del Canto1, Claudia Cárcamo1, Lorena Garcia1,2
1Departamento de Neurología, Pontificia Universidad Católica de Chile, Santiago, Chile.
概括
在患有多发性硬化症 (MS) 的西班牙裔/拉丁裔个体中,ocrelizumab表现出有效性和一致的安全性. 这项现实研究强调了它在代表性不足的人群中的好处.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 现实世界的研究对于了解临床试验中历史上代表性不足的人群的治疗结果至关重要.
- 奥克雷利祖马布是多发性硬化症 (MS) 的重要治疗选择,但不同种族群体的数据有限.
研究的目的:
- 评估ocrelizumab在被诊断患有多发性硬化症 (MS) 的西班牙裔/拉丁裔个体中的安全性和有效性.
- 评估ocrelizumab对疾病活动,残疾进展和现实环境中的安全的影响.
主要方法:
- 进行了一项前性的纵向观察性研究.
- 参与者包括305名患有多发性硬化症 (pwMS) 的患者,他们在2018年6月至2023年10月期间至少服用了一剂ocrelizumab.
- 收集的数据包括人口统计,疾病特征,扩展残疾状况尺度 (EDSS),复发率,残疾恶化,MRI活动和不良事件.
主要成果:
- 在所有MS表型中,ocrelizumab治疗与显著降低的磁共振成像 (MRI) 活动有关.
- 在12.4%的患者中观察到低复发率 (1名患者) 和12周确认的残疾恶化;SPMS显示风险更高.
- 安全性概况是一致的,4.6%的患者出现严重感染. 在研究期间报告了22例怀孕.
结论:
- 奥克雷利祖马布在拉丁裔/拉丁裔多发性硬化症 (MS) 患者的现实世界队列中有效.
- 该药物在接受专业多发性硬化病单位护理的这个代表性不足的人群中表现出一致的安全性.
- 研究结果支持ocrelizumab在多种多发性硬化症患者群体中的实用性.
相关概念视频
Treatment Resistant Cancers
2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Clinical Trials
8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.5K
Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
897
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
Multiple Sclerosis l: Introduction
31
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
31
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
59
Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet...
59


